News

Dr. Annie Levine joins the lab

Dr. Annie Levine joins the lab as a clinical fellow. Annie is a fellow in pediatric gastroenterology at Seattle Children’s Hospital. She graduated from Harvard with a BA in Slavic Languages and Literatures and earned her MD at the University of Pittsburgh in 2017. After completing her residency in pediatrics at Brown University in Providence, RI, she moved to Seattle in 2020 to start her clinical fellowship.
Annie has been doing research in inflammatory bowel disease since 2011, examining disease complications, the interplay between inflammation and mood, and interactions between the gut microbiome, diet, and the pathogenesis of intestinal inflammation. She looks forward to adding computational methods to her clinical and statistical tool kit in order to identify potential targets for innovative dietary and therapeutic interventions in inflammatory bowel disease.
Outside the lab, Annie enjoys sailing, scuba diving, cooking, opera, annoying her cats (Greylien and Pippin), and hiking with her corgi, Oliver, and husband David.

Recent Articles

  • Building a Better BMI

    ISB researchers have constructed biological body mass index (BMI) measures that offer a more accurate representation of metabolic health and are more varied, informative and actionable than the traditional, long-used BMI equation. The work was published in the journal Nature Medicine. 

  • Dr. Sean Gibbons Promoted to Associate Professor

    Dr. Sean Gibbons – an expert in microbial ecology and evolution, computational systems biology, the human gut microbiome and its impacts on health, and head of ISB’s Gibbons Lab – has been promoted to Associate Professor. “Sean’s achievements since joining ISB in 2018 as a Washington Research Foundation Distinguished Investigator have been spectacular,” ISB President Dr. Jim Heath said. “With his focus on the microbiome, he brought a whole new…

  • The Gut Microbiome’s Supersized Role In Shaping Our Metabolome

    ISB researchers have shown which blood metabolites are associated with the gut microbiome, genetics, or the interplay between both. Their findings, published in the journal Nature Metabolism, have promising implications for guiding targeted therapies designed to alter the composition of the blood metabolome to improve human health.